US equities |
MU $1,074.67 ▼-1.23% META $721.78 ▲+0.07% NVDA $234.15 ▼-1.40% PLTR $202.66 ▲+4.40% GOOGL $353.74 ▲+0.92% SNDK $1,660.82 ▼-1.87% AMD $634.62 ▼-1.74% INTC $109.72 ▼-3.01%
FinancialContent

Fsd Pharma Inc Cl B (CSE:HUGE)

0.1250 UNCHANGED
Last Price Updated: 3:58 PM EDT, Aug 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Fsd Pharma Inc Cl B

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
FSD Pharma Announces Filing of Year-End 2021 Results
From FSD Pharma Inc.
Via Business Wire
InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Spotlighted in Recent EIO Report from Crystal Research Associates
Via Investor Brand Network
News headline image
FSD Pharma Announces Executive Informational Overview Report Produced by Crystal Research Associates LLC
From FSD Pharma Inc.
Via Business Wire
BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Enters Agreement for Sale of Cobourg Facility for CAD$16.5M
Via Investor Brand Network
Topics Cannabis
News headline image
FSD Pharma Announces Agreement for Sale of Cobourg Facility for CAD$16,500,000
From FSD Pharma Inc.
Via Business Wire
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) Unveils Newly Designed Website
Via Investor Brand Network
BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) Unveils Newly Designed Corporate Website
Via Investor Brand Network
News headline image
FSD Pharma Announces Launch of New Corporate Website
From FSD Pharma Inc.
Via Business Wire
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) Board Member Named to the Order of Canada
Via Investor Brand Network
InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Board Member Named to the Order of Canada
Via Investor Brand Network
News headline image
FSD Pharma Congratulates Dr. Eleanor Fish on Being Named to the Order of Canada
From FSD Pharma Inc.
Via Business Wire
InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Participation in Upcoming H.C. Wainwright Bioconnect Conference
Via Investor Brand Network
News headline image
FSD Pharma to Present at the H.C. Wainwright Bioconnect Conference on January 10-13th
From FSD Pharma Inc.
Via Business Wire
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Board Approves Share Repurchase Program
Via Investor Brand Network
InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Board Approves Share Repurchase Program
Via Investor Brand Network
News headline image
FSD Pharma Announces Share Repurchase Program
From FSD Pharma Inc.
Via Business Wire
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) Shares Preclinical Data Demonstrating Positive Effects of Lucid-MS in Treating MS
Via Investor Brand Network
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) Announces Establishment of Advisory Board, Strategic Appointments
Via Investor Brand Network
News headline image
FSD Pharma Establishes New Regulatory Advisory Board with the Appointment of Joga Gobburu, Ph.D., and Mary Melnyk, Ph.D., as Members
From FSD Pharma Inc.
Via Business Wire
News headline image
FSD Pharma to Present at the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference on December 6th
From FSD Pharma Inc.
Via Business Wire
News headline image
The Power Play by the Market Herald Releases New Interviews With Lumiera, Fsd Pharma, HydroGraph, and Adastra Holdings
VANCOUVER, BC / ACCESSWIRE / December 2, 2021 / The Power Play by The Market Herald has announced the release of new interviews with Lumiera, FSD Pharma, HydroGraph, and Adastra Holdings discussing... 
From The Market Herald
Via AccessWire
News headline image
FSD Pharma Unveils Videos Demonstrating Positive Effects of Lucid-MS in Treating Multiple Sclerosis in Pre-Clinical Models (Mouse Models)
From FSD Pharma Inc.
Via Business Wire
News headline image
FSD Pharma Expands Research and Clinical Advisory Board with Appointment of World-Renowned Immunologist and Cytokine Expert Dr. Eleanor N. Fish
From FSD Pharma Inc.
Via Business Wire
Ketamine’s Potential As A Treatment For Depression Has Drawn Major Industry Attention
Palm Beach, FL –October 27, 2021 – FinancialNewsMedia.com News Commentary – Among the race to see what psychedelic drugs can do, ketamine is a step ahead of all other drugs, because it has already been... 
Via FinancialNewsMedia
News headline image
FSD Pharma Signs Agreement with Covar Pharmaceuticals to Support the Development of Lucid-PSYCH
From FSD Pharma Inc.
Via Business Wire
News headline image
FSD Pharma Announces Engagement with Capital Markets Communications Providers and Market Maker
From FSD Pharma Inc.
Via Business Wire
News headline image
FSD Pharma Announces Closing of Lucid Psycheceuticals Acquisition
From FSD Pharma Inc.
Via Business Wire
News headline image
FSD Pharma Announces Definitive Agreement to Acquire Lucid Psycheceuticals
From FSD Pharma Inc.
Via Business Wire
News headline image
FSD Pharma Inc. Announces Termination of FSD-201 Phase 2 Clinical Trial
From FSD Pharma Inc.
Via Business Wire
News headline image
FSD Pharma Inc. Announces Termination of Chief Executive Officer Dr. Raza Bokhari for Cause
From FSD Pharma Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >